STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.
<p>Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.</p>